Clinical analysis of Paclitaxel and Platinum in Recurrent Carcinoma of the Uterine Cervix / 대한산부인과학회지
Korean Journal of Obstetrics and Gynecology
;
: 1448-1455, 2005.
Article
in Korean
| WPRIM
| ID: wpr-14107
ABSTRACT
OBJECTIVE:
This study was performed to evaluate the efficacy and the toxicity of paclitaxel and platinum in patients with recurrent cervical carcinoma.METHODS:
Twenty nine patients were treated with paclitaxel 135-175 mg/m2 and cisplatin 50-75 mg/m2 or carboplatin at AUC 5 every 3 weeks for a maximum of six courses from January 2001 to January 2004.RESULTS:
A total 134 cycles with paclitaxel and platinum were administered. Ten patients (34.2%) achieved an objective response, including four complete responses (13.6%) and six partial responses (20.6%). Overall survival was 13.2 months, and the response and non-response group were 23.2 and 8.1 months, respectively (p=0.01). Clinical response according to recurrent site was significantly different (p=0.048) but, survival was not (p=0.22). Grade 3 or 4 granulocytopenia in 75.9% of patients was developed and one expired due to neutropenic sepsis after first cycle chemotherapy.CONCLUSION:
The combination of paclitaxel and platinum seems relatively well tolerated and has 34.2% response rate in patients with recurrent cervical cancer. Further study for this combination chemotherapy and prognostic factor should be needed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Platinum
/
Uterine Cervical Neoplasms
/
Cervix Uteri
/
Carboplatin
/
Cisplatin
/
Paclitaxel
/
Sepsis
/
Area Under Curve
/
Agranulocytosis
/
Drug Therapy
Type of study:
Prognostic study
Limits:
Female
/
Humans
Language:
Korean
Journal:
Korean Journal of Obstetrics and Gynecology
Year:
2005
Type:
Article
Similar
MEDLINE
...
LILACS
LIS